[Independent (Kampala)] The rising threat of antimicrobial resistance (AMR) continues to expose deep structural weaknesses in global pharmaceutical markets, with drug-resistant infections projected to claim nearly two million lives annually by 2050 unless investment and policy responses accelerate, according to the 2026 AMR Benchmark published by the Access to Medicine Foundation.